Information to Consider

Recently joined after finding an old chart and becomming curious what happened to CYDY. Still own a few shares. I've been aware of CytoDyn since the pandemic and was impacted negatively by everything that happened back then. I asked Gemini a couple of questions which I thought may be of value to others on this board. TL;DR the potential scenarios at the end may be beneficial to some who are thinking about share price potential. Good luch to all.

Q: how many outstanding shares are there of cydy?

As of May 6, 2025, the number of CytoDyn Inc.'s (CYDY) outstanding shares is approximately 1.23 billion. This figure is based on recent reports and stock data.  

It's worth noting that the number of outstanding shares can fluctuate due to various corporate actions such as stock issuance, stock buybacks, or stock splits. For the most up-to-date information, you can refer to the company's filings with the U.S. Securities and Exchange Commission (SEC), such as quarterly (10-Q) and annual (10-K) reports, which are typically available on the SEC's EDGAR database or the investor relations section of CytoDyn's website.

CytoDyn Inc. is a clinical-stage biotechnology company focused on the development of innovative treatments for multiple therapeutic indications using its lead drug candidate, leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor. The company has been exploring leronlimab's potential in various areas, including HIV, COVID-19, and cancer. However, it's important to note that investing in clinical-stage biotech companies carries significant risk, as the success of their drug development programs is uncertain.  

Q: Is this more or less than other similar companies?

CytoDyn's approximately 1.23 billion outstanding shares is significantly higher than many other similar-sized biotechnology companies.

Here's a breakdown of why this is the case and some context:

General Context of Outstanding Shares in Biotech:

• Biotechnology companies, especially those in the clinical stage like CytoDyn, often have a history of raising capital through the issuance of new shares. This is because drug development is a long, expensive, and high-risk process, and companies may not have revenue to fund operations until (and if) a drug is approved and commercialized.
• The number of outstanding shares can vary greatly depending on the company's financing history, stage of development, and market capitalization.
• Smaller market capitalization biotech companies might have anywhere from a few million to a few hundred million outstanding shares. Mid-cap and large-cap biotechs can have hundreds of millions or even billions of shares.

Why CytoDyn's Number is High for its Size:

• Historical Fundraising: CytoDyn has been a publicly traded company for a while and has likely raised capital through multiple equity offerings over the years to fund its research and development activities for leronlimab across various indications. Each offering would have increased the number of outstanding shares.
• Stock Price: A lower stock price can sometimes correlate with a higher number of outstanding shares for a given market capitalization. CytoDyn's stock price has historically been relatively low, which means it would need more shares outstanding to achieve its current market capitalization (approximately $400 million as of May 6, 2025).
• Potential Dilution: The high number of outstanding shares can be a point of concern for investors as it can lead to dilution. Dilution occurs when a company issues more shares, which can decrease the ownership percentage of existing shareholders and potentially lower the earnings per share and the stock price.

Comparison to Peers:

It's difficult to give an exact average for "similar companies" without specifying factors like market capitalization, stage of development, and therapeutic focus. However, generally speaking, a company with a market cap around $400 million would typically have significantly fewer outstanding shares than 1.23 billion.

For example, looking at some other biotech companies:

• IO Biotech (IOBT), with a market capitalization around $65 million, has approximately 65.88 million outstanding shares (as of April 2025).
• Many small to mid-cap biotech companies listed on NASDAQ with market caps in the hundreds of millions to a few billion dollars often have outstanding shares in the range of 20 million to 200 million, although this is a broad range.

CytoDyn's 1.23 billion outstanding shares stands out as a high number for a company of its current market capitalization and stage.

In summary, CytoDyn has a considerably larger number of outstanding shares compared to many other biotechnology companies of similar market capitalization. This is likely a result of its past fundraising activities and its stock price history.

Q: what is a target share price if one of it's indications hit?

It's impossible to provide a precise target share price for CytoDyn if one of its indications hits a positive milestone. This is because stock prices of biotechnology companies are highly speculative and influenced by numerous factors beyond just clinical trial results. However, we can discuss the potential impact and some considerations:

Factors Influencing Target Price:

• Specific Indication: The target price would heavily depend on the indication that achieves success. A breakthrough in a large market with unmet needs (e.g., a significant advancement in oncology) would likely have a much greater impact than success in a smaller market.
• Market Size and Competition: The potential revenue from the successful indication is crucial. What is the size of the patient population? What are the existing treatments and their effectiveness? A first-in-class or best-in-class treatment would command a higher market share.  
• Clinical Trial Data: The strength and significance of the clinical trial results are paramount. Did the drug meet its primary and secondary endpoints with statistical significance? Were the safety and tolerability profiles favorable?
• Regulatory Approval: Positive trial results are just one step. Regulatory approval (e.g., from the FDA in the United States) is necessary for commercialization. The likelihood and speed of approval will influence investor sentiment.  
• Commercialization Strategy: How will CytoDyn bring the drug to market? Will they partner with a larger pharmaceutical company? Their own commercial infrastructure and expertise will be evaluated.
• Overall Market Conditions and Investor Sentiment: The broader economic environment and the overall appetite for risk in the biotech sector will play a role.
• Company Financials: CytoDyn's cash position, debt, and burn rate will be considered in the valuation.
• Dilution: As discussed previously, CytoDyn has a large number of outstanding shares. Further stock issuance to fund development or commercialization could dilute the value of existing shares.  

Potential Scenarios (Illustrative and Highly Speculative):

It's important to remember these are purely illustrative and not financial advice:

• Success in a Smaller Market (e.g., a specific inflammatory condition): If leronlimab shows compelling efficacy in a smaller, niche market with limited competition, the stock price could see a significant percentage increase, perhaps moving it into the $1 - $3 range initially, depending on the market size and potential revenue. However, the overall market capitalization might not increase as dramatically as with a larger indication.
• Significant Breakthrough in a Larger Market (e.g., a subtype of cancer like mTNBC with strong survival data): A major breakthrough in a large oncology market with strong clinical data demonstrating a significant improvement in survival or progression-free survival could lead to much more substantial gains. In such a scenario, the stock price could potentially jump to the $5 - $15+ range or even higher, especially if analysts project multi-billion dollar peak sales. Recent data showing promising survival outcomes in mTNBC patients treated with leronlimab has been noted, and further positive results could be very impactful.  
• Success in HIV (e.g., as a long-acting monotherapy for resistant patients): While the HIV market is established, a novel therapy like a long-acting monotherapy for drug-resistant patients could capture a significant portion. Estimates for the CCR5 antagonist market in HIV are in the billions of dollars. Success here could potentially move the stock price into the $3 - $8 range, depending on the market penetration and pricing.

It is crucial to understand:

• These are highly speculative ranges. Actual results could be significantly higher or lower.
• The market will react based on the specifics of the news. The magnitude of the price change will depend on how groundbreaking and commercially viable the successful outcome appears to be.
• Long-term success depends on further development, regulatory approvals in other regions, and successful commercialization.

For investors, it's essential to conduct thorough due diligence, understand the risks involved in investing in clinical-stage biotech companies, and not rely solely on potential future successes. Keep an eye on clinical trial results, regulatory filings, and company announcements for the most up-to-date information.